Ovarian Reserve in Intensive Care Patients

NCT ID: NCT06999291

Last Updated: 2025-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-15

Study Completion Date

2025-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gastrointestinal, pulmonary, nephrological, cardiac, neurologic and psychological effects in critically ill patients followed in the intensive care unit have been shown in the literature. However, the effects on ovarian reserve in these patients have not been sufficiently investigated and studies investigating this issue are limited in the literature. The synthesis, release frequency and amplitude of reproductive hormones change under stress. In addition, changes in ovarian homeostasis affect ovarian reserve. The aim of this study was to evaluate ovarian reserve in critically ill patients followed up in the intensive care unit.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anti-Mullerian Hormone Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

internal intensive care

Patients hospitalized in intensive care for internal reasons

Glaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS)

Intervention Type BEHAVIORAL

The uterus, endometrium and ovarian characteristics, endometrial thickness, ovarian follicle number and ovarian volume parameters, hormone panel (FSH, LH, E2, AMH), cortisol, prolactin and thyroid function tests routinely examined for ovarian reserve will be evaluated in the study.

surgical intensive care

Patients hospitalized in intensive care for surgical reasons

Glaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS)

Intervention Type BEHAVIORAL

The uterus, endometrium and ovarian characteristics, endometrial thickness, ovarian follicle number and ovarian volume parameters, hormone panel (FSH, LH, E2, AMH), cortisol, prolactin and thyroid function tests routinely examined for ovarian reserve will be evaluated in the study.

Outpatient clinic patients

Healthy female patients admitted to gynecology outpatient clinic

Glaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS)

Intervention Type BEHAVIORAL

The uterus, endometrium and ovarian characteristics, endometrial thickness, ovarian follicle number and ovarian volume parameters, hormone panel (FSH, LH, E2, AMH), cortisol, prolactin and thyroid function tests routinely examined for ovarian reserve will be evaluated in the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS)

The uterus, endometrium and ovarian characteristics, endometrial thickness, ovarian follicle number and ovarian volume parameters, hormone panel (FSH, LH, E2, AMH), cortisol, prolactin and thyroid function tests routinely examined for ovarian reserve will be evaluated in the study.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-35 years of age
* Female patients followed in the intensive care unit for more than 24 hours for internal or surgical reasons,
* Women whose ovarian reserve is being evaluated,

Exclusion Criteria

* Previous ovarian surgery, endometriosis, endometrioma,
* History of chemotherapy, radiotherapy,
* Ovarian cyst, malignancy and other ovarian pathologies,
* Women with single ovary,
* Women receiving hormone therapy,
* Polycystic ovary syndrome,
* Surgical intervention within the last 6 months,
* History of drug, alcohol, substance use,
* Women in pregnancy, puerperium, lactation,
* History of vaccination within the last 6 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Haseki Training and Research Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Emine Yilmaz Guler

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

emine yılmaz güler

Role: CONTACT

Phone: 905054525261

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Kayambankadzanja RK, Schell CO, Gerdin Warnberg M, Tamras T, Mollazadegan H, Holmberg M, Alvesson HM, Baker T. Towards definitions of critical illness and critical care using concept analysis. BMJ Open. 2022 Sep 5;12(9):e060972. doi: 10.1136/bmjopen-2022-060972.

Reference Type RESULT
PMID: 36606666 (View on PubMed)

Moolhuijsen LME, Visser JA. Anti-Mullerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020 Nov 1;105(11):3361-73. doi: 10.1210/clinem/dgaa513.

Reference Type RESULT
PMID: 32770239 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OR-2024

Identifier Type: -

Identifier Source: org_study_id